AR and adenocarcinoma: We performed IHC to measure the expression of PROX1 along with NCAM1, AR, and the AR target, PSA, using tissue sections from samples collected at multiple time points (i.e., pre-castration adenocarcinoma [LTL331], 12 weeks post-castration, and relapsed NEPC [LTL331R]).